JPWO2021182571A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021182571A5
JPWO2021182571A5 JP2021531941A JP2021531941A JPWO2021182571A5 JP WO2021182571 A5 JPWO2021182571 A5 JP WO2021182571A5 JP 2021531941 A JP2021531941 A JP 2021531941A JP 2021531941 A JP2021531941 A JP 2021531941A JP WO2021182571 A5 JPWO2021182571 A5 JP WO2021182571A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531941A
Other languages
English (en)
Japanese (ja)
Other versions
JP7715041B2 (ja
JPWO2021182571A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/009796 external-priority patent/WO2021182571A1/ja
Publication of JPWO2021182571A1 publication Critical patent/JPWO2021182571A1/ja
Publication of JPWO2021182571A5 publication Critical patent/JPWO2021182571A5/ja
Application granted granted Critical
Publication of JP7715041B2 publication Critical patent/JP7715041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531941A 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品 Active JP7715041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020043019 2020-03-12
JP2020043019 2020-03-12
PCT/JP2021/009796 WO2021182571A1 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Publications (3)

Publication Number Publication Date
JPWO2021182571A1 JPWO2021182571A1 (https=) 2021-09-16
JPWO2021182571A5 true JPWO2021182571A5 (https=) 2024-02-28
JP7715041B2 JP7715041B2 (ja) 2025-07-30

Family

ID=77671704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531941A Active JP7715041B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Country Status (7)

Country Link
US (1) US20230165957A1 (https=)
EP (1) EP4119158A4 (https=)
JP (1) JP7715041B2 (https=)
KR (1) KR20220152309A (https=)
BR (1) BR112022018166A2 (https=)
CA (1) CA3175127A1 (https=)
WO (1) WO2021182571A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) * 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
AU2022298240A1 (en) * 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
MX340015B (es) * 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR101842893B1 (ko) * 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
HUE025678T2 (en) * 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) * 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740793T (pt) * 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び/又は予防用医薬組成物
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
PT2818483T (pt) * 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
EP3752154A4 (en) * 2018-02-12 2021-12-29 Array Biopharma, Inc. Methods and combination therapy to treat biliary tract cancer
JP7342701B2 (ja) * 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP2020043019A (ja) 2018-09-12 2020-03-19 トヨタ自動車株式会社 燃料電池

Similar Documents

Publication Publication Date Title
JPWO2021182573A5 (https=)
EP4582100A1 (en) Medicament for treatment and/or prevention of cancer
EP3777888A1 (en) Pharmaceutical composition for treatment and/or prevention of cancer
EP4119156A1 (en) Medicament for treatment and/or prevention of cancer
US20250228937A1 (en) Medicament for treatment and/or prevention of cancer
JPWO2021182571A5 (https=)
JPWO2021182574A5 (https=)
JPWO2021182570A5 (https=)
TW202128176A (zh) 使用蛋白精胺酸甲基轉移酶5(prmt5)抑制劑之每日一次癌症治療方案
CN111246881B (zh) Pd-1抗体用于治疗肿瘤的用途
JP7715041B2 (ja) 癌の治療及び/又は予防のための医薬品
JP7793986B2 (ja) 癌の治療及び/又は予防のための医薬品
JPWO2021182572A5 (https=)
US20230159635A1 (en) Medicament for treatment and/or prevention of cancer
JP7793985B2 (ja) 癌の治療及び/又は予防のための医薬品
WO2019107341A1 (ja) オゾンナノバブルの抗がん剤
EP4422757A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
EP4360648A1 (en) Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) Medicament for treatment and/or prevention of cancer
US20260115285A1 (en) Medicament for treatment and/or prevention of cancer
EP4578459A1 (en) Pharmaceutical product for treatment and/or prevention of cancer
EP4578458A1 (en) Medicament for treatment and/or prevention of cancer
EP4578457A1 (en) Pharmaceutical for treating and/or preventing cancer
US20260115267A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
EP4640235A1 (en) Medicament for treatment and/or prevention of cancer